[Adjuvant therapy of locally advanced prostate carcinoma with ibandronate].
Lindenmeir
T
T
MVZ Urologie, Krankenhaus Barmherzige Brüder, Prüfeninger Strasse 86, 93049 Regensburg. urologie@barmherzige-regensburg.de
Ulrich
M
M
Rau
O
O
Reiher
F
F
Allhoff
E P
EP
D014408:Biomarkers, Tumor / Q000097:blood; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D000077557:Ibandronic Acid; D007262:Infusions, Intravenous; D008134:Long-Term Care; D008297:Male; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D017430:Prostate-Specific Antigen; D000077557:Ibandronic Acid